Table 1.
Basic characteristics of literature research.
| Study ID | Sample size | Age (year) | Duration | Follow-up time | Intervention | Control | SBP dosage | Outcomes | ||
|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | |||||||
| Sun, [14] | 64 | 64 | 72.55 ± 3.63 | 72.34 ± 3.46 | 6 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ① |
| Huang, [15] | 30 | 30 | 56.81 ± 12.61 | 55.11 ± 12.32 | 12 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ④ |
| Xu, [16] | 100 | 100 | 59.76 ± 10.43 | 59.36 ± 10.13 | 3 months | 12 months | SBP + control | PCI + CT | 1 pill, t.i.d. | ①④⑤⑥ |
| Feng, [17] | 45 | 45 | 62.8 ± 5.1 | 62.5 ± 4.8 | 1 month | 12 months | SBP + control | PCI + CT | 3 pills, t.i.d. | ①④⑤ |
| Si, [18] | 60 | 60 | 50.13 ± 11.27 (total) | 6 months | 18 months | SBP + control | PCI + CT | 2 pills, t.i.d. | ①④⑤ | |
| Jia, [19] | 37 | 35 | 55.00 ± 10.73 | 60.31 ± 11.67 | 6 months | 6 months | SBP + control | PCI + CT | 2 pills, t.i.d. | ③ |
| Hu, [20] | 50 | 50 | 58.0 ± 8.7(total) | 12 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ① | |
| Gao, [21] | 51 | 51 | NR | 12 months | 12 months | SBP + control | PCI + CT | 2 pills, t.i.d. | ①② | |
| Zhang, [22] | 60 | 50 | 48.10 ± 5.12 | 48.15 ± 5.10 | 6 months | NR | SBP + control | PCI + CT | 2 pills, b.i.d. | ①④ |
| Song, [23] | 50 | 50 | 56.4 ± 8.6 | 55.9 ± 7.7 | 3 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ①②③⑥ |
| Yu, [24] | 60 | 60 | 62.41 ± 4.33 | 62.53 ± 4.42 | 1 month | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ② |
| Wei, [25] | 36 | 36 | 65.25 ± 6.30 | 64.90 ± 6.16 | 3 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ②④ |
| Ran, [26] | 100 | 100 | 61.00 ± 10.33 | 62.31 ± 12.07 | 12 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ③⑤ |
| Jia, [27] | 38 | 38 | 61.3 ± 8.9 | 59.8 ± 9.1 | 2 months | NR | SBP + control | PCI + CT | 3 pills, t.i.d. | ① |
| Zhang, [28] | 55 | 55 | 60.5 ± 9.1 | 61.7 ± 10.3 | 4 weeks | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ①②③⑥ |
| Song, [29] | 33 | 33 | 73.92 ± 8.11 | 73.29 ± 8.03 | 16 weeks | NR | SBP + control | PCI + CT | 1 pill, t.i.d. | ①②⑥ |
| Shi, [30] | 40 | 40 | 66.8 ± 6.9 | 68.2 ± 7.5 | 3 months | NR | SBP + control | PCI + CT | 2 pills, t.i.d. | ①② |
| Ma, [31] | 60 | 56 | 62.17 ± 8.33 | 61.96 ± 7.45 | 4 weeks | 3 months | SBP + control | PCI + CT | 2 pills, t.i.d. | ①② |
| Sun [32] | 50 | 50 | 61 ± 3 | 61 ± 3 | 1 week | 4 weeks | SBP + control | PCI + CT | 2 pills, t.i.d. | ①② |
Notes: T, trial group; C, control group; NR, not report; SBP, Shexiang Baoxin Pill; PCI, percutaneous coronary intervention; CT, conventional treatment; t.i.d., three times a day; b.i.d., two times a day; ① MACE ② LVEF; ③ NT-pro-BNP; ④ inflammatory mediators; ⑤ blood lipid index; ⑥ adverse reactions.